|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The Xeroderma-Pigmentosum group-D polymorphism at codon-751 (XPD-Lys751Gln) emerged as the most significant independent predictor for death- and progression-risk in our previous study on functional polymorphisms in 122 advanced pancreatic cancer patients treated with cisplatin-docetaxel-capecitabine-gemcitabine and cisplatin-epirubicin-capecitabine-gemcitabine (or EC-GemCap).
|
23390054 |
2013 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No association was found between p53 mutations and either XPD Lys751Gln or XRCC1 Arg399Gln.
|
12844488 |
2003 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In summary, this meta-analysis suggests the XPD Lys751Gln polymorphism is a genetic susceptibility for some cancer types.
|
25113251 |
2014 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Whether the single nucleotide polymorphism (SNP) Lys751Gln of xeroderma pigmentosum group D(XPD) gene increases susceptibility to head and neck cancer (HNC) is controversial and undetermined.
|
24443924 |
2014 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The ERCC1 rs13181 and XPD rs11615 polymorphisms were not predictive of clinical outcome for HCC patients receiving TACE (both p > 0.05).
|
26918371 |
2016 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data suggest that Asian populations have a significantly lower prevalence of codon 751 Lys/Gln polymorphism in XPD, which could be a key determinant for good response to oxaliplatin-based treatment and favorable outcomes.
|
19432884 |
2009 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A significant association was observed between X</span>PD</span> K75</span>1Q polymorphism and the risk of NPC using conditional logistic regression.
|
26086338 |
2015 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
XPD Lys751Gln (A>C) may have inverse predictive and prognostic role in platinum-based treatment of NSCLC according to different ethnicities.
|
24260311 |
2013 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We conducted a case-control study to investigate the association of Human apurinic/apyrimidinic (AP) endonuclease (APEX1) Asp148Glu (rs1130409), Xeroderma Pigmentosum group D (XPD) Lys751Gln (rs13181), X-ray repair cross-complementing group 1 (XRCC) Arg399Gln (rs25487) and X-ray repair cross-complementing group 3 (XRCC3) Thr241Met (rs861539) polymorphisms with PE in a Mexican population.
|
24619222 |
2014 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For the single nucleotide polymorphisms in XRCC1 exon 10 (Arg399Gln, G/A) and XPD exon 23 (Lys751Gln, A/C), no remarkable differences for genotype distribution and allele frequencies were observed between BC group and control group in the study.
|
18415712 |
2008 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To determine whether the XRCC1 (codon Arg399Gln) and XPD (codon Asp312Asn and codon Lys751Gln) polymorphisms are associated with prostate cancer susceptibility, we genotyped these polymorphisms in a primarily Caucasian sample of 506 sibships (n = 1,117) ascertained through a brother with prostate cancer.
|
14744728 |
2004 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This is the first study on DNA repair genetic polymorphisms in West Algerian population, and it suggests that the XRCC3 Thr241Met and XPD Lys751Gln polymorphisms may not be associated with the CRC risk in this population.
|
24687779 |
2014 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition XPD rs13181 was also found to be associated with male POAG patients (χ(2) = 12.1 [p < 0.005]), for both dominant (OR = 2.44 [95% CI = 1.33-4.47], p < 0.005) as well as recessive model (OR = 3.62 [95% CI = 1.45-9.01], p < 0.01).
|
21617750 |
2011 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We conclude that XPD Lys751Gln polymorphism may be an important marker in the prediction of clinical outcome to platinum-based chemotherapy.
|
11751380 |
2001 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We aimed to determine the associations of genetic polymorphisms of excision repair cross-complementation group 1 (ERCC1) rs11615, xeroderma pigmentosum group D (XPD/ERCC2) rs13181, X-ray repair cross complementing group 1 (XRCC1) rs25487, XRCC3 rs1799794, and breast cancer susceptibility gene 1 (BRCA1) rs1799966 from the DNA repair pathway and multiple drug resistance 1 (MDR1/ABCB1) rs1045642 with response to chemotherapy and survival of non-small cell lung cancer (NSCLC) in a Chinese population.
|
24933103 |
2014 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This meta-analysis suggested that XPD Lys751Gln polymorphism might be a risk factor for AML and Caucasian acute leukemia patients.
|
24486506 |
2014 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No clear association between XPD Asp312Asn or XPD Lys751Gln gene polymorphisms and lung cancer was found.
|
15615908 |
2005 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
|
12844488 |
2003 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The genotypes of XPD Asp312Asn (p=0.2493), Lys751Gln (p=0.7547) and promoter -114 (p=0.8702), were not associated with susceptibility for colorectal cancer.
|
27069143 |
2016 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two commonly studied single nucleotide polymorphisms (SNPs) of XPD (Lys751Gln, A>C, rs13181; Asp312Asn, G>A, rs1799793) are implicated in the modulation of DNA repair capacity, thus related to the responses to platinum-based chemotherapy.
|
24260311 |
2013 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The Xeroderma pigmentosum group D (XPD, also referred to as excision repair cross complementing gene 2, ERCC2) is one of key genes involved in nucleotide excision repair and two potentially functional polymorphisms of XPD (Asp312Asn and Lys751Gln) have been widely investigated in various cancers including prostate cancer.
|
23771356 |
2014 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our investigations demonstrate that XPD Asn312Asp SNP not the Gln751Lys SNP, might poorly increase PCa risk in Asians and Africans, moreover, this SNPs may associate with the tumor stage of PCa.
|
23028604 |
2012 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Numerous epidemiological studies have been conducted to investigate the association between Xeroderma pigmentosum complementation group D (XPD) Asp312Asn (rs1799793 G > A) and Lys751Gln (rs13181 A > C) polymorphisms and bladder cancer risk; however, the conclusions remain controversial.
|
24347488 |
2014 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
XPD Asp312Asn (rs1799793) of Han ethnic was associated with a borderline decrease of ESCC (OR: 0.362, 95% CI: 0.145-0.906), however, it was associated with ESCC risk in Uygur ethnic (OR: 2.403, 95% CI: 1.087-5.310).
|
21553048 |
2012 |
|
rs1799793
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The correlation between ERCC1 polymorphisms (rs11615 and rs3212986) and XPD polymorphisms (rs13181 and rs1799793) with the response rate and overall survival of cancer patients who accept neoadjuvant therapy has been extensively investigated.However, the results are inconclusive.
|
26426637 |
2015 |